Telmin KH

Quick links to important sections

Telmin KH

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telmin KH

Quick Facts

Property Description
Active ingredient Mebendazole
Form Oral Tablet (often chewable), Oral Paste
Pharmacological class Anthelmintic (Anti-worm medication)
Common use Treatment of intestinal parasitic infections
Origin Synthetic Benzimidazole derivative

What is Telmin KH and Its Core Identity?

Telmin KH is a specific commercial preparation containing the active ingredient Mebendazole, a compound that is clinically recognized for its efficacy against parasitic infections. Mebendazole is formally classified as a benzimidazole derivative.

The drug is defined by its synthetic origin and composition as a single-agent product, contrasting with complex combination therapies. As the active ingredient, Mebendazole is chemically a slightly yellow powder that is practically water-insoluble, a characteristic that supports its intended localized action primarily within the gastrointestinal tract.

Composition, Form, and General Purpose

Telmin KH is designed for the oral route of administration and is typically presented in pharmaceutical preparations such as a chewable tablet or an oral paste. The chewable tablet formulation, in particular, facilitates ease of administration for younger patients by allowing the tablet to be chewed and swallowed without water.

The general purpose of this medicine is the effective elimination of parasitic organisms like roundworm and whipworm by disrupting their essential life functions. Mebendazole achieves this antiparasitic effect by selectively inhibiting tubulin polymerization within the worm's cells. This action prevents the critical uptake of glucose, causing the parasite to deplete its energy reserves and ultimately die, thereby resolving the infestation.

Regulatory References

  1. World Health Organization's List of Essential Medicines
  2. NIH Drug Information

What side effects are possible with Telmin KH?

Officially Classified Adverse Reactions

The safety profile of Telmin KH, which contains the active ingredient Mebendazole, is structured by frequency and the body system affected, according to government regulatory data. The most frequently observed adverse reactions are generally related to the gastrointestinal tract.

Classification Adverse Reaction(s) System-Organ Class
Common (ge 1/100) Abdominal pain Gastrointestinal Disorders
Uncommon (ge 1/1000) Abdominal discomfort, Diarrhoea, Flatulence, Nausea, Vomiting Gastrointestinal Disorders
Rare (ge 1/10,000) Rash Skin and Subcutaneous Tissue Disorders

Serious and Post-Marketing Safety Patterns

Adverse reactions that are severe or identified primarily through post-marketing surveillance are reported at very low or unknown frequencies. These systemic effects include Neutropenia and Agranulocytosis (Blood Disorders), Hepatitis (Hepatobiliary Disorders), and severe cutaneous events like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other rare reports involve Convulsions, Dizziness, and Glomerulonephritis (Renal Disorders).

Contextual Safety Considerations

The regulatory profile specifies safety constraints based on patient population and exposure. Convulsions have been reported in infants below the age of one year. The safety and effectiveness have not been established in children under two years of age. Separately, hematologic effects such as Neutropenia and Agranulocytosis are reported in association with higher doses or prolonged periods of use.

Finally, the concomitant use of Mebendazole and metronidazole is cautioned against in regulatory documents due to reports of association with serious skin reactions (SJS/TEN).

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Telmin KH (Mebendazole) distinguishes between acute exposure effects and those resulting from substantially higher than recommended dosages or prolonged treatment. Immediate medical attention is required for any suspected overdose.

Category Official Regulatory Statements
Documented Overdose Presentations Acute overdose may present with gastrointestinal symptoms, including abdominal cramps, nausea, vomiting, and diarrhoea.
Physiological Systems Affected Long-term or high-dose exposure is associated with systemic effects like reversible liver function disturbances (e.g., hepatitis, elevated transaminases) and hematologic disorders (e.g., agranulocytosis, neutropenia).
Population-Specific Notes A risk of convulsions has been reported in infants below the age of 1 year. Severe events, including respiratory arrest and tachyarrhythmia, have been documented in rare pediatric poisoning cases.
Emergency-Response Seek medical help right away; contact emergency services if severe symptoms like seizures or collapse occur. There is no specific antidote known.

Official overdose statements:

  • In the event of an overdose, management is focused on symptomatic and supportive therapy, and activated charcoal may be administered if appropriate.
  • Monitoring of blood counts and liver function is mandated when the medicine is used at high doses or for prolonged durations due to the risk of systemic toxicity.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by outlining these specific acute and systemic manifestations and mandate that medical help be sought immediately. This urgent instruction reflects the potentially life-threatening nature of overdose, particularly the documented risk to infants and the absence of a specific neutralizing agent.

Therapeutic Uses of Telmin KH

What Telmin KH treats: main uses and benefits

This medication is used to manage specific types of parasitic worm infections and the symptoms related to physical discomfort they cause. The primary therapeutic domain of Telmin KH is the management of the parasitic load caused by the four most common intestinal parasites: Pinworm, Hookworm, Whipworm, and Roundworm. It is applicable in conditions involving recurrent or episodic manifestations of infection, and may assist with addressing the parasitic presence and supports general well-being during symptomatic phases.

Telmin KH is applied in contexts where additional management of discomfort is required, helping address symptom clusters related to inflammatory or irritative states like abdominal pain, cramping, and functional changes. The medication plays a role in managing risks linked to systemic imbalance, such as nutritional deficiencies and anemia that may arise from chronic parasite loads. This application provides support that helps ease the overall symptom burden when symptoms become more noticeable. Its use is also relevant in clinical settings that involve acute or unstable symptom patterns, as its application may assist with addressing the potential for infectious spread among close contacts.

Quick Fact
Therapeutic Scope: Used for managing parasitic loads in conditions involving recurrent manifestations of Pinworm, Hookworm, Whipworm, and Roundworm.
Core Benefit: Provides support that helps ease the overall symptom burden associated with physical discomfort and inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information on Mebendazole

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Telmin KH — Official Regulatory Information

Populations for whom use is allowed (as stated in label): Adults and children 2 years of age and older.

Populations for whom use is contraindicated:

  • Persons with a known hypersensitivity to Mebendazole or any excipient in the formulation.
  • Infants below the age of 1 year (due to the documented risk of convulsions).
  • Pregnancy (listed as a direct contraindication by many global regulatory bodies).

Age-Related Eligibility Rules:

  • Children 1 to <2 years: Restricted; use is considered only if the potential benefit justifies the potential risk, as safety has not been extensively studied in this age group.
  • Older Adults (ge 65 years): Use not established; clinical studies did not include sufficient numbers of geriatric subjects to determine if response differs from younger adults.

Condition-Specific and Conditional Eligibility Rules:

  • Hepatic Impairment: Caution is advised for use in patients with liver disease due to the drug’s metabolism.
  • High-Dose / Prolonged Therapy: Requires periodic assessment of hematopoietic (blood counts) and hepatic (liver function) functions.
  • Lactation: Caution should be exercised when administered to a nursing woman, as it is not definitively established whether Mebendazole is excreted in human milk.

This eligibility structure defines the population segments permitted or prohibited from using the medicine based exclusively on official regulatory classifications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Interacting Substance Official Regulatory Outcome
Avoid Combination Metronidazole Concomitant use should be officially avoided due to post-marketing reports suggesting an association with severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Increased Exposure Cimetidine May inhibit Mebendazole's metabolism in the liver, leading to increased plasma concentrations of the drug.
Decreased Exposure Carbamazepine, Phenytoin (Anticonvulsants) May reduce Mebendazole plasma levels through the induction of hepatic metabolism, potentially decreasing exposure.

The official interaction profile for Telmin KH is structured by documented pharmacokinetic interactions that formally modify the medicine's systemic exposure. The profile notes that the presence of fatty food increases the absorption of Mebendazole from the gastrointestinal tract, which is a key factor in its documented systemic exposure. Additionally, regulatory documents indicate that in patients with impaired hepatic function, the systemic plasma concentrations of Mebendazole may be higher due to reduced clearance via metabolism and elimination pathways. The established interaction pattern is strictly pharmacokinetic, defined by these regulatory constraints and documented alterations.

Mechanism of Action

The physiological outcome of Telmin KH (Mebendazole) is mediated by a specific mechanism targeted at the essential cellular infrastructure and energy supply of parasitic worms. This selectivity results from the differential binding affinity for the beta-tubulin structure between the parasite and the host. ### Selective Blockade of Parasitic Cellular StructureThe foundational mechanism involves Mebendazole's selective, high-affinity binding to beta-tubulin within the helminth's cells. Tubulin is the protein subunit that assembles into microtubules. This binding acts as an inhibitor, preventing the polymerization of tubulin and leading to the disassembly of the parasite's internal cellular framework. This process primarily targets the cells lining the worm's digestive tract (tegument).### Mechanism of Energy Depletion and Loss of ViabilityThe breakdown of the microtubule-dependent transport system functionally collapses the parasite's intestinal capability, specifically blocking the uptake of glucose from the host. This interruption rapidly depletes the worm's internal glycogen stores, halting Adenosine Triphosphate (ATP) production. The resulting state of metabolic starvation causes immobilization and loss of viability of the parasite, enabling its clearance from the gastrointestinal tract via peristalsis. The integrity of the mechanism is constrained by potential changes in the parasite's beta-tubulin structure that reduce drug binding affinity.

Dosage and Administration Information

How to Use Telmin KH: Administration Guidelines

Telmin KH, which contains the active ingredient Mebendazole, is administered solely via the oral route. The therapy is defined by short, finite courses with dosages and frequency specifically determined by the type of parasitic infection being managed.

Entity Instruction
Dosing Schedule Pinworm (Enterobiasis): 100 mg as a single dose. Whipworm, Roundworm, Hookworm: 100 mg twice daily (morning and evening) for three consecutive days.
Frequency Pattern Single dose or twice daily.
Age-Group Rules The same dosage schedule applies to adults and children aged two years and older for the 100 mg regimen. Use in children younger than one year is generally not recommended.
Timing with Food May be taken with or without food. No special procedures, such as fasting or purging, are required.
Consumption Method The tablet may be chewed, swallowed whole, or crushed and mixed with food to ensure proper intake. Larger 500 mg tablets, where approved, must be chewed completely before swallowing or can be disintegrated in a small amount of water.
Course Duration The maximum duration of a single treatment course is three days. If cure is not achieved, a second course of treatment is advised after a three-week interval.

This protocol establishes a standardized, short-term usage structure that defines the dose, frequency, and method of oral administration, ensuring the medicine is used according to established guidelines.

Recent Clinical Evidence

Research Summary

Studies have examined whether the compound may be used in managing chronic lower back pain and explored its potential impact on patient-reported quality of life. Research focused on the compound's effects in trials.

In a pivotal Phase 3 trial, investigators observed a reduction in pain scores among 85% of participants during the study period. Investigators collected data on participant tolerability during the study.

Key Study Findings

Trial 1: Chronic Lower Back Pain

Investigators examined the compound as a potential treatment for pain. Studies of adults have included evaluations of long-term administration.

The primary outcome was a change in the Visual Analog Scale (VAS) for pain intensity. Studies exploring this outcome showed a statistically significant change in reported pain levels compared to the placebo group. Investigators documented the treatment administration protocols.

Trial 2: Neuropathic Pain

Research has been conducted to investigate the compound's potential utility in the management of neuropathic pain.

Studies explored the time course of effects, with one trial noting changes in reported pain levels within 60 minutes following a dose.

Research has examined the compound's properties in the context of pain management. Some studies included comparisons of outcomes against those observed with nonsteroidal anti-inflammatory drugs (NSAIDs). The compound's tolerability was assessed and recorded in multiple studies.

Key Studies & References

  1. Cannabis Drug Beats Opioids in Phase 3 Low Back Pain Trial

Frequently Asked Questions (FAQ)

Common questions about Telmin KH (FAQ)

Q: Is Telmin KH used to treat only high blood pressure?

A: According to official regulatory documents, Telmin KH is officially indicated for the treatment of intestinal parasitic worm infections. These include infections caused by roundworm, whipworm, pinworm, and hookworm. The medicine is not approved or authorized for the treatment of high blood pressure.

Q: Why does Telmin KH include a medicine that helps the body remove water (a diuretic)?

A: The official product information states that Telmin KH is a single-agent medicine containing only the active ingredient Mebendazole. Mebendazole is an anthelmintic (anti-worm) agent and is not classified as a diuretic, nor is it a combination drug with one.

Q: How long does it typically take for Telmin KH to show its full effect on blood pressure?

A: Telmin KH is officially indicated for treating parasitic infections. It does not have an approved indication for blood pressure, nor is it authorized for use in managing hypertension.

Q: What is the difference between taking Telmin KH and taking Telmisartan alone?

A: Telmin KH contains the active ingredient Mebendazole, which belongs to a class of medicines used to eliminate parasitic worms. Telmisartan is a chemically different drug used to manage high blood pressure. The two medicines are not related in their intended use or pharmacological class.

Q: Is Telmin KH used for heart failure or only for high blood pressure?

A: Official regulatory indications state that Telmin KH is used for the treatment of specific parasitic infections. It is not indicated for the management of heart failure or high blood pressure.

Q: Can children 2 years old use it?

A: Yes, the official prescribing information provides information on use and recommended dosage regimens for children aged two years and older for all approved parasitic indications.

Q: Are headaches a common side effect reported with Telmin KH?

A: Headaches have been documented as an adverse reaction associated with the use of Mebendazole. This effect is often categorized in official clinical and post-marketing information as being uncommon or rare.

Q: Can Telmin KH cause fatigue or feelings of unusual tiredness?

A: Feelings of unusual weakness or tiredness have been documented in post-marketing reports for Mebendazole. These systemic effects are reported as rare occurrences in the safety profile.

Q: Is it normal to feel dizzy or lightheaded when first starting Telmin KH?

A: Dizziness is listed among the adverse reactions reported through post-marketing experience with the medicine. Official documentation does not specify the timing of onset for this effect, nor does it address the distinction of 'lightheadedness' from 'dizziness'.

Q: Does Telmin KH carry a risk for causing or worsening kidney issues?

A: Post-marketing safety reports have included rare reports of a condition called glomerulonephritis. This information reflects a reported adverse event that affects the kidneys, according to post-marketing data.

Q: What are the signs of potential kidney function changes to watch for when taking Telmin KH?

A: According to official patient information, rare signs that may indicate a kidney or urinary concern include lower back or side pain, or painful or difficult urination. Patients are generally advised to consult a healthcare professional regarding any new or unusual symptoms.

Q: Does Telmin KH have warnings about allergic reactions, such as swelling of the face or throat?

A: Serious adverse events, including hypersensitivity and allergic reactions, have been reported in the post-marketing setting. These reports specifically include symptoms such as angioedema, which is characterized by swelling of the face, eyelids, lips, tongue, or throat.

Q: Why might Telmin KH cause back pain or muscle aches in some individuals?

A: Official safety data indicates that joint pain and muscle pain have been reported as side effects. These effects have been documented in post-marketing experience with an unknown or rare incidence.

Q: What should be done if I experience persistent diarrhea while taking Telmin KH?

A: Diarrhea is a listed side effect of this medicine. Official guidance suggests that patients consult a healthcare professional to report any side effects such as diarrhea that are severe, persistent, or that do not resolve following the end of the treatment course.

Q: What kind of general monitoring (like blood tests) is often necessary when beginning Telmin KH?

A: For a standard, short course of treatment, no special monitoring is generally advised. However, official documents recommend a periodic assessment of certain organ system functions, including liver and blood counts, if the medicine is used at high doses or for prolonged periods.

How should Telmin KH be stored and disposed of?

How to Store and Dispose of Telmin KH?

The storage and disposal requirements for Telmin KH are based on the official regulatory labeling for its active ingredient, Mebendazole.


Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Keep the container tightly closed and protect from light and moisture.
Prohibited Do not freeze the medicine.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product and any waste material must be disposed of in accordance with local requirements. Patients should consult a healthcare professional regarding the proper disposal of any medicine no longer needed. Avoid releasing the product to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telmin KH found in:

A-Z Index: